Uman Pharma develops and manufactures cytotoxic and high‑potent sterile injectable and solid dosage products for the oncology market, offering both proprietary and generic formulations. The company operates a manufacturing site in Candiac, Canada, where it produces specialized oncology products. Uman’s product focus is on high‑value, regulated oncology medications that require specialized sterile manufacturing. The recent equity investment will finance a substantial increase in the number of specialized oncology products developed and manufactured in Candiac for commercialization worldwide. Management expects to leverage the investor’s commercial capabilities to expand reach into regulated markets. The company’s core operations remain centered on sterile oncology product development and contract manufacturing.

Total raised

$27M

Funding rounds

1

Latest round

Equity

Latest activity

Nov 2011